Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04539808
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:38.431591+00:00
Published At
2026-01-14T00:00:00+00:00
Record Updated At
2026-01-14
Results Posted At
2026-01-14
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Pancreatic Adenocarcinoma", "Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8", "Stage I Pancreatic Cancer American Joint Committee on Cancer v8", "Stage III Pancreatic Cancer American Joint Committee on Cancer v8", "Stage IV Pancreatic Cancer American Joint Committee on Cancer v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-14"
protocolSection.identificationModule.nctId
"NCT04539808"
protocolSection.identificationModule.officialTitle
"NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2026-01-14"

Study condition terms

  • Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8 (protocolSection.conditionsModule.conditions)
  • Stage I Pancreatic Cancer American Joint Committee on Cancer v8 (protocolSection.conditionsModule.conditions)
  • Stage III Pancreatic Cancer American Joint Committee on Cancer v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Pancreatic Cancer American Joint Committee on Cancer v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.